81 Investor presentation First six months of 2023 Oral amycretin entered phase 1 i and peptide expertise with oral te Amycretin is a GLP-1 and amylin receptor co-agonist intended for oral delivery GLP-1 receptor Amylin receptor Utilising the SNAC technology PK: Pharmacokinetics; PD: Pharmacodynamics
Download PDF file